Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Roland E. Andersson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0778-8630; OpenAlex author ID A5054165373, A5108150978, A5158658156. Sources: OpenAlex.

Their work

Papers
87 (first author 18, last author 41)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 8 papers · 2014: 5 papers · 2015: 7 papers · 2016: 4 papers · 2017: 11 papers · 2018: 7 papers · 2019: 11 papers · 2020: 3 papers · 2021: 3 papers · 2022: 3 papers · 2023: 4 papers · 2024: 7 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 87

  1. Reliance on topographical coding alone may overestimate survival in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.sipas.2026.100357↗
  2. Digital quantification of stroma percentage enhances prognostic stratification in pancreatic cancer. First author DOI 10.1016/j.sopen.2026.01.002↗
  3. Transcriptomic profiling reveals autophagy-associated programs and prognostic biomarkers in anoikis-resistant pancreatic cancer cells. Co-author DOI 10.1186/s12885-026-17107-7↗
  4. Prognostic model establishment and immune microenvironment analysis based on transcriptomic data of long-term survivors of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrep.2025.102280↗
  5. Early Detection of Sporadic Pancreatic Cancer First author DOI 10.1159/000545424↗
  6. Biomarkers for Early Detection of Pancreatic Cancer. First author DOI 10.1159/000546584↗
  7. A Tissue-based Biomarker Risk Score for Predicting Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/cdp.10496↗
  8. Histological variants of pancreatic ductal adenocarcinoma: a survival analysis. First author DOI 10.1007/s00423-024-03506-6↗
  9. Anoikis-related genes linked with patient outcome in pancreatic cancer. Co-author DOI 10.1016/j.gene.2024.148868↗
  10. Microbiome alterations in pancreatic cancer: new insights and potential clinical implications. Last author DOI 10.1080/00365521.2023.2261062↗
  11. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Last author DOI 10.1080/00365521.2024.2378948↗
  12. Prediagnostic blood biomarkers for pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrae046↗
  13. L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.1177/10732748241251583↗
  14. Surveillance after resection of pancreatic ductal adenocarcinoma: How to do it and what are the benefits? Co-author DOI 10.1177/14574969231156353↗
  15. Neoadjuvant chemo(radio)therapy in upfront resectable pancreatic cancer - can we stratify patients better in the future? Co-author DOI 10.1080/00365521.2022.2100226↗
  16. Model-based screening for pancreatic cancer in Sweden. Last author DOI 10.1080/00365521.2022.2142481↗
  17. Acute pancreatitis – one key to early detection of pancreatic cancer? Co-author DOI 10.1080/00365521.2023.2281251↗
  18. Pancreatic cancer screening in high-risk individuals with genetic susceptibility Co-author DOI 10.21037/hbsn-23-237↗
  19. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-021-02685-8↗
  20. Pancreatic cancer - the past, the present, and the future. Co-author DOI 10.1080/00365521.2022.2067786↗
  21. Surgical resection of pancreatic cancer with synchronous hepatic oligometastases: Real benefit or selection bias? First author DOI 10.1177/14574969221096513↗
  22. Organoid technology for personalized pancreatic cancer therapy. First author DOI 10.1007/s13402-021-00585-1↗
  23. Macropinocytosis: the Achilles' heel of pancreatic cancer? Last author DOI 10.1080/00365521.2020.1855471↗
  24. Projected economic burden of pancreatic cancer in Sweden in 2030. Last author DOI 10.1080/0284186x.2021.1892821↗
  25. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12094-020-02372-0↗
  26. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. First author DOI 10.1038/s41598-020-73525-y↗
  27. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. Co-author DOI 10.1186/s12967-020-02254-7↗
  28. Early-onset pancreatic cancer: a population-based study using the SEER registry. Last author DOI 10.1007/s00423-019-01810-0↗
  29. Proteomic and genomic profiling of pancreatic cancer. Last author DOI 10.1007/s10565-019-09465-9↗
  30. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. First author DOI 10.1016/j.ebiom.2019.04.008↗
  31. Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ijsu.2019.09.014↗
  32. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. First author DOI 10.1016/j.trsl.2019.06.003↗
  33. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1080/00365521.2018.1561937↗
  34. Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. Last author DOI 10.1080/00365521.2019.1574360↗
  35. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12957-019-1574-z↗
  36. The Role of PEDF in Pancreatic Cancer. Last author DOI 10.21873/anticanres.13473↗
  37. The Hippo Signaling Pathway in Pancreatic Cancer. Last author DOI 10.21873/anticanres.13474↗
  38. Is immunotherapy the holy grail for pancreatic cancer? Co-author DOI 10.2217/imt-2019-0164↗
  39. Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancer patients with type 2 diabetes. Last author DOI 10.1016/j.pan.2017.11.003↗
  40. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm. First author DOI 10.1080/00365521.2018.1532020↗
  41. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-018-5013-2↗
  42. Targeting dendritic cells in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12935-018-0585-0↗
  43. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.23929↗
  44. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment. Last author DOI 10.18632/oncotarget.24019↗
  45. Centrosomal Abnormalities in Pancreatic Cancer: Molecular Mechanisms and Clinical Implications. Last author DOI 10.21873/anticanres.12345↗
  46. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/bjs.10471↗
  47. Characterization of histone-related chemical modifications in formalin-fixed paraffin-embedded and fresh-frozen human pancreatic cancer xenografts using LC-MS/… Co-author DOI 10.1038/labinvest.2016.134↗
  48. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Last author DOI 10.1080/00365521.2017.1290134↗
  49. Pancreatic cancer stroma: controversies and current insights. Last author DOI 10.1080/00365521.2017.1293726↗
  50. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma. First author DOI 10.1080/00365521.2017.1301989↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Ansari · 73 shared papers, 2011–2026 · strength 11.58
  2. Monika Posaric Bauden · 30 shared papers, 2013–2026 · strength 3.46
  3. Axel Bengtsson · 7 shared papers, 2019–2026 · strength 1.90
  4. Bodil Andersson · 12 shared papers, 2013–2026 · strength 1.50
  5. Dingyuan Hu · 10 shared papers, 2018–2020 · strength 1.01
  6. Qimin Zhou · 10 shared papers, 2018–2020 · strength 1.01
  7. Ragnar Norrsell · 3 shared papers, 2024–2025 · strength 0.92
  8. Bobby Tingstedt · 8 shared papers, 2011–2024 · strength 0.88
  9. Lizhi Lin · 3 shared papers, 2024–2025 · strength 0.84
  10. Tomasz Draus · 3 shared papers, 2021–2024 · strength 0.79
  11. György Marko‐Varga · 9 shared papers, 2014–2020 · strength 0.70
  12. Caj H. Haglund · 2 shared papers, 2022–2024 · strength 0.59
  13. William Falk · 1 shared paper, 2026 · strength 0.50
  14. Ann H. Rosendahl · 8 shared papers, 2011–2018 · strength 0.45
  15. Lizhi Lin · 1 shared paper, 2026 · strength 0.43
  16. Hanna E. Seppänen · 2 shared papers, 2022–2024 · strength 0.38
  17. Matthias J. Löhr · 2 shared papers, 2012–2025 · strength 0.34
  18. Emelie Karnevi · 5 shared papers, 2012–2018 · strength 0.33
  19. Aistė Gulla · 1 shared paper, 2025 · strength 0.33
  20. Xian Shen · 1 shared paper, 2025 · strength 0.33
  21. Thilo Hackert · 1 shared paper, 2025 · strength 0.30
  22. Iréne Esposito · 1 shared paper, 2025 · strength 0.30
  23. Hans Scherübl · 1 shared paper, 2025 · strength 0.30
  24. Daniel Kříž · 1 shared paper, 2025 · strength 0.28
  25. Linus Aronsson · 3 shared papers, 2014–2019 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.